# (19) World Intellectual Property Organization

International Bureau



# A 1864 A BARANTAN KARANTAN BARANTAN BARANTAN KANTAN BARANTAN BARANTAN BARANTAN BARANTAN BARANTAN BARANTAN BARA

### (43) International Publication Date 10 March 2005 (10.03.2005)

## (10) International Publication Number WO 2005/021001 A1

- A61K 31/505, (51) International Patent Classification<sup>7</sup>: 31/52, 31/513, A61P 31/18 // (A61K 31/52, 31:513, 31:505) (A61K 31/513, 31:505) (A61K 31/52, 31:505)
- (21) International Application Number:

PCT/EP2004/052028

(22) International Filing Date:

3 September 2004 (03.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

EP 3 September 2003 (03.09.2003) 03103275.8 US 3 September 2003 (03.09.2003) 60/499,771 8 September 2003 (08.09.2003) EP 03103319.4 10 September 2003 (10.09.2003) EP 03103335.0 2 October 2003 (02.10.2003) EP 03103668.4 3 October 2003 (03.10.2003) US 60/508,486

- (71) Applicant (for all designated States except US): TI-BOTEC PHARMACEUTICALS Ltd.? [IE/IE]; Little Island, Co Cork (IE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): STOFFELS, Paul? [BE/BE]; Lindendreef 34, B-2320 Hoogstraten (BE).
- (74) Agent: WANTE, Dirk?; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS

(57) Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI named TMC278 with nucleoside reverse transcriptase inhibitors such as emtricitabine, lamivudine or abacavir and/or nucleotide reverse transcriptase inhibitors such as tenofovir useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.

